Logo image of IGC

IGC PHARMA INC (IGC) Stock Fundamental Analysis

NYSEARCA:IGC - NYSE Arca - US45408X3089 - Common Stock - Currency: USD

0.3025  +0 (+1.17%)

After market: 0.3098 +0.01 (+2.41%)

Fundamental Rating

1

Overall IGC gets a fundamental rating of 1 out of 10. We evaluated IGC against 195 industry peers in the Pharmaceuticals industry. IGC has a bad profitability rating. Also its financial health evaluation is rather negative. IGC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IGC has reported negative net income.
In the past year IGC has reported a negative cash flow from operations.
In the past 5 years IGC always reported negative net income.
In the past 5 years IGC always reported negative operating cash flow.
IGC Yearly Net Income VS EBIT VS OCF VS FCFIGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

IGC's Return On Assets of -97.04% is on the low side compared to the rest of the industry. IGC is outperformed by 73.85% of its industry peers.
IGC has a Return On Equity of -140.74%. This is in the lower half of the industry: IGC underperforms 63.08% of its industry peers.
Industry RankSector Rank
ROA -97.04%
ROE -140.74%
ROIC N/A
ROA(3y)-84.76%
ROA(5y)-60.82%
ROE(3y)-105.88%
ROE(5y)-74.42%
ROIC(3y)N/A
ROIC(5y)N/A
IGC Yearly ROA, ROE, ROICIGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 51.46%, IGC is in the better half of the industry, outperforming 64.62% of the companies in the same industry.
In the last couple of years the Gross Margin of IGC has grown nicely.
IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y64.59%
GM growth 5Y84.65%
IGC Yearly Profit, Operating, Gross MarginsIGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IGC has more shares outstanding
The number of shares outstanding for IGC has been increased compared to 5 years ago.
The debt/assets ratio for IGC is higher compared to a year ago.
IGC Yearly Shares OutstandingIGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IGC Yearly Total Debt VS Total AssetsIGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

IGC has an Altman-Z score of -16.01. This is a bad value and indicates that IGC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.01, IGC is doing worse than 76.92% of the companies in the same industry.
IGC has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
IGC has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: IGC outperforms 55.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -16.01
ROIC/WACCN/A
WACC9.78%
IGC Yearly LT Debt VS Equity VS FCFIGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

IGC has a Current Ratio of 1.15. This is a normal value and indicates that IGC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IGC (1.15) is worse than 80.00% of its industry peers.
A Quick Ratio of 0.61 indicates that IGC may have some problems paying its short term obligations.
With a Quick ratio value of 0.61, IGC is not doing good in the industry: 87.69% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 0.61
IGC Yearly Current Assets VS Current LiabilitesIGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

IGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.96%, which is quite impressive.
Looking at the last year, IGC shows a small growth in Revenue. The Revenue has grown by 0.98% in the last year.
IGC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -23.46% yearly.
EPS 1Y (TTM)51.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.09%
Revenue 1Y (TTM)0.98%
Revenue growth 3Y14.33%
Revenue growth 5Y-23.46%
Sales Q2Q%25.98%

3.2 Future

The Earnings Per Share is expected to grow by 16.99% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.48% on average over the next years.
EPS Next Y61.42%
EPS Next 2Y26.15%
EPS Next 3Y16.99%
EPS Next 5YN/A
Revenue Next Year0.24%
Revenue Next 2Y8.04%
Revenue Next 3Y6.48%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IGC Yearly Revenue VS EstimatesIGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
IGC Yearly EPS VS EstimatesIGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IGC. In the last year negative earnings were reported.
Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGC Price Earnings VS Forward Price EarningsIGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGC Per share dataIGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as IGC's earnings are expected to grow with 16.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.15%
EPS Next 3Y16.99%

More info and screens

0

5. Dividend

5.1 Amount

IGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGC PHARMA INC

NYSEARCA:IGC (6/20/2025, 8:04:00 PM)

After market: 0.3098 +0.01 (+2.41%)

0.3025

+0 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-18 2025-06-18
Earnings (Next)08-05 2025-08-05
Inst Owners20.94%
Inst Owner ChangeN/A
Ins Owners3.33%
Ins Owner Change0%
Market Cap24.11M
Analysts80
Price Target3.95 (1205.79%)
Short Float %0.8%
Short Ratio2.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.13%
Min EPS beat(2)8.5%
Max EPS beat(2)23.75%
EPS beat(4)2
Avg EPS beat(4)-218.05%
Min EPS beat(4)-890.1%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.51%
Min Revenue beat(2)0.97%
Max Revenue beat(2)38.04%
Revenue beat(4)3
Avg Revenue beat(4)12.37%
Min Revenue beat(4)-40.88%
Max Revenue beat(4)51.34%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)14.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.5
P/FCF N/A
P/OCF N/A
P/B 3.85
P/tB 5.49
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.02
BVpS0.08
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.04%
ROE -140.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.46%
FCFM N/A
ROA(3y)-84.76%
ROA(5y)-60.82%
ROE(3y)-105.88%
ROE(5y)-74.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y64.59%
GM growth 5Y84.65%
F-Score4
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.07%
Cap/Sales 51.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 0.61
Altman-Z -16.01
F-Score4
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)96.21%
Cap/Depr(5y)762.55%
Cap/Sales(3y)97.14%
Cap/Sales(5y)115.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.09%
EPS Next Y61.42%
EPS Next 2Y26.15%
EPS Next 3Y16.99%
EPS Next 5YN/A
Revenue 1Y (TTM)0.98%
Revenue growth 3Y14.33%
Revenue growth 5Y-23.46%
Sales Q2Q%25.98%
Revenue Next Year0.24%
Revenue Next 2Y8.04%
Revenue Next 3Y6.48%
Revenue Next 5YN/A
EBIT growth 1Y24.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.38%
OCF growth 3YN/A
OCF growth 5YN/A